Alector Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2013)

Organization Overview

First Clinical Trial
2018
NCT03636204
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Alector Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

al001 (5 trials)

Drugs in Phase 2 Trials (2)

al002 (3 trials)

gsk4527226 (1 trial)

Drugs in Phase 1 Trials (2)

al101 (1 trial)

latiglutenase (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Aphasia, Primary Progressive (Phase 3)

Dementia (Phase 3)

Frontotemporal Dementia (Phase 3)

Pick Disease of the Brain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5